EP3206487A1 - Utilisation d'ester d'acide gras pour améliorer l'efficacité antimicrobienne d'un désinfectant à base d'alcool - Google Patents

Utilisation d'ester d'acide gras pour améliorer l'efficacité antimicrobienne d'un désinfectant à base d'alcool

Info

Publication number
EP3206487A1
EP3206487A1 EP15781614.1A EP15781614A EP3206487A1 EP 3206487 A1 EP3206487 A1 EP 3206487A1 EP 15781614 A EP15781614 A EP 15781614A EP 3206487 A1 EP3206487 A1 EP 3206487A1
Authority
EP
European Patent Office
Prior art keywords
disinfectant
weight
less
relative
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15781614.1A
Other languages
German (de)
English (en)
Other versions
EP3206487B1 (fr
Inventor
Angelo Da Silva Nolasco
Petra Kolditz
Katrin Steinhauer
Sylvia BOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schuelke and Mayr GmbH
Original Assignee
Schuelke and Mayr GmbH
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54330743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3206487(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schuelke and Mayr GmbH, LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical Schuelke and Mayr GmbH
Priority to PL15781614T priority Critical patent/PL3206487T3/pl
Publication of EP3206487A1 publication Critical patent/EP3206487A1/fr
Application granted granted Critical
Publication of EP3206487B1 publication Critical patent/EP3206487B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N31/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic oxygen or sulfur compounds
    • A01N31/02—Acyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the invention relates to an alcoholic disinfectant and the disinfectant for use for hygienic and for surgical disinfection of the hands.
  • the invention further relates to the use of fatty acid ester for improving the antimicrobial efficacy of an alcoholic disinfectant.
  • ethanol- based disinfectants are recommended (including the product desderman ® pure from Schulke & Mayr GmbH with a content (according to manufacturer's data) of 78.2 g ethanol (96%) and 0.1 g biphenyl-2-ol in 100 g) .
  • Glycerin is therefore a widely used substance as refatting agent in commercial formulations for alcoholic disinfection of the hands (cf. for example the commercial products Sterillium ® classic and Sterillium ® med from Bode Chemie GmbH, Hamburg, Federal Republic of Germany) .
  • WO2014/032696 Al discloses virucidal alcoholic hand disinfectants.
  • the presence of glycerin is mandatory.
  • agents with virucidal action are not necessarily effective against all microorganisms against which hand disinfectants must be effective.
  • investigations with glycerin-containing formulations have shown that the presence of glycerin inhibits the bactericidal properties of alcoholic hand disinfectants for surgical disinfection of the hands according to EN 12791 (Suchomel, M., Rotter, M. Weinlich, M., Kundi, M. (2013). J Hosp Infect 83 : 284-7) .
  • WO2006/122345 Al describes agents for treating areas of skin before surgery.
  • the glycerin-free gel as humectant disclosed for example in WO 2006/122345 Al, contains relatively little ethanol (70 wt%) .
  • it contains triclosan, which is assessed critically by the Federal Institute for Risk Assessment of the Federal Republic of Germany (FRG) , cf. Opinion No. 30/2006 dated 8 May 2006, namely because bacteria such as Salmonella enterlca, Escherichia coll, Pseudomonas aeruginosa and Staphylococcus aureus have mechanisms for developing resistance to triclosan.
  • WO 2009/088894 A2 discloses skin disinfectants containing C2 to C5 alcohol. They may also contain humectant esters.
  • the teaching includes esters of alkane diacids, especially the diisopropyl esters of adipic acid (hexane diacid) and sebacic acid (decane diacid) .
  • esters of alkane diacids especially the diisopropyl esters of adipic acid (hexane diacid) and sebacic acid (decane diacid) .
  • the efficacy of a disinfectant largely depends on the alcohol used and its concentration in the disinfectant (or the mixture of alcohols used and the concentration thereof) .
  • the present invention is based on the problem of supplying refatting agents for ethanolic disinfectants, wherein the refatting agents in the disinfectant should not, in contrast to glycerin, have an inhibitory effect on the antimicrobial efficacy, especially when they are to be used at higher concentration. It was found that this problem is solved according to the invention by using fatty acid ester of monovalent Ci to C6 alkyl alcohol. Thus, according to the invention it was found, surprisingly, that addition of a fatty acid ester as refatting agent to an alcoholic disinfectant leads, with increasing concentration, even to an improvement in efficacy in the quantitative suspension test according to DGHM, in contrast to addition of glycerin as refatting agent.
  • the invention therefore relates, in a first aspect, to an alcoholic disinfectant that comprises a) at least 78 wt% ethanol, relative to the weight of the disinfectant, and
  • the disinfectant according to the invention thus comprises less than 0.1 wt% glycerin, preferably less than 0.05 wt%, especially less than 0.03 wt%, for example less than 0.01 wt% glycerin, in each case relative to the weight of the disinfectant .
  • the alcoholic disinfectant according to the invention contains at least 78 wt% ethanol, preferably at least 78.5 wt%, preferably at most 98 wt%, more preferably at most 97 wt%, such as 79.0 to 96 wt%, especially 79.5 to 95 wt%, such as 80 to 94 wt%, for example 81 to 93 wt%, especially 81.5 to 92.5 wt% ethanol, in each case relative to the weight of the disinfectant .
  • the stated ethanol content thus refers to the pure substance (and does not include denaturing agent or water contained for example in ethanol of technical or medical purity) .
  • Disinfectants according to the invention contain b) one or more fatty acid esters of monovalent Ci to C6 alkyl alcohol.
  • the alkyl alcohol of the fatty acid ester is selected from methanol, ethanol, n- and i-propanol. Especially preferably, the alkyl alcohol of the fatty acid ester is in particular i-propanol.
  • the fatty acid of the fatty acid ester is selected from Cio to Cis fatty acids, preferably C12 to Ci6 fatty acids, wherein the fatty acid is preferably myristic acid.
  • component b) is isopropyl myristate.
  • Component b) preferably isopropyl myristate, is present in the disinfectant according to the invention preferably in an amount from 0.02 to 5 wt%, relative to the weight of the disinfectant, preferably 0.1 to 4 wt%, more preferably 0.2 to 3 wt%, especially 0.3 to 2.0 wt%, such as 0.5 to 1.8 wt%, for example 0.6 to 1.6 wt%, such as 0.75 or about 1.4 wt%. Further constituents of the disinfectant
  • disinfectants according to the invention may further optionally contain: c) Fatty alcohol
  • the fatty alcohol is preferably selected from Cio to Cis fatty alcohols, preferably C12 to Ci6 fatty alcohols, wherein the fatty alcohol is preferably myristyl alcohol.
  • Component c) preferably myristyl alcohol, is present in the disinfectant according to the invention preferably in an amount from 0.02 to 5 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 4 wt%, for example 0.5 to 1.5 wt%, such as 1.0 wt%.
  • Diol preferably diol
  • Preferred diols contained in the disinfectant according to the invention are propanediol-1 , 2 and propanediol-1 , 3.
  • Component d) is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.4 to 1.0 wt%, for example about 0.5 or about 0.8 wt%.
  • Component d) is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.4 to 1.0 wt%, for example about 0.5 or about 0.8 wt%.
  • bispyridinium alkane comprises the bis- [4- (substituted-amino) -1-pyridinium] -alkanes of general formulae (I) or (II) disclosed in DE 27 08 331 C2
  • Y is an alkylene group with 4 to 18 carbon atoms
  • R denotes an alkyl group with 6 to 18 carbon atoms or a cycloalkyl group with 5 to 7 carbon atoms or the phenyl residue, which is substituted with a halogen atom, and
  • A is an anion or several anions.
  • A may of course also be a polyvalent anion, e.g. phosphate or orthosilicate .
  • bispyridinium alkane comprises the various prototropes of the compounds of formula (I), as is disclosed for example in DE 196 47 692 Al .
  • Component e) is thus especially preferably octenidine.
  • Preferred amounts of component e) in the disinfectant according to the invention are 0.005 to 1.0 wt%, preferably 0.01 to 0.5 wt%, more preferably 0.03 to 0.3 wt%, even more preferably 0.04 to 0.2 wt%, such as 0.05 to 0.15 wt%, for example about 0.1 wt%, in each case relative to the total weight of the disinfectant.
  • chlorhexidine derivative is chlorhexidine gluconate .
  • Component f) is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.3 to 1.0 wt%, for example about 0.4 wt%.
  • Glycerin ether is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.3 to 1.0 wt%, for example about 0.4 wt%.
  • 1- (2-ethylhexyl) glycerin ether) is preferably 0.01 to 1 wt%, relative to the weight of the disinfectant, preferably 0.02 to 0.5 wt%, such as 0.05 to 0.3 wt%, for example about 0.2 wt%.
  • Fatty acid fatty alcohol ester is preferably 0.01 to 1 wt%, relative to the weight of the disinfectant, preferably 0.02 to 0.5 wt%, such as 0.05 to 0.3 wt%, for example about 0.2 wt%.
  • Disinfectants according to the invention preferably contain h) fatty acid fatty alcohol esters.
  • the fatty alcohol of the fatty acid fatty alcohol ester is preferably selected from Ci o to Cis fatty acids, preferably C12 to Ci 6 fatty acids, and is for example cetearyl alcohol.
  • the fatty acid of the fatty acid fatty alcohol ester is preferably selected from short-chain fatty acids, such as C4 to C12 fatty acids, especially Cs to Ci o fatty acids, wherein the fatty acid is preferably octanoic acid. Therefore in all embodiments of the present invention it is preferred that component h) is cetearyl octanoate.
  • Component h) preferably cetearyl octanoate, is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.3 to 1.0 wt%, for example about 0.8 wt%.
  • Polyvinylpyrrolidone preferably polyvinylpyrrolidone
  • An excipient preferably contained in the disinfectant according to the invention is polyvinylpyrrolidone, preferably povidone K, especially povidone K30.
  • Component i) i.e. polyvinylpyrrolidone, is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.4 to 1.0 wt%, for example about 0.3 wt%.
  • Sugar alcohol i.e. polyvinylpyrrolidone
  • the disinfectant according to the invention contains j) sugar alcohol, for example sorbitol.
  • Component j) is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.3 to 1.0 wt%, for example about 0.5 wt%.
  • Antioxidant is present in the disinfectant according to the invention preferably in an amount from 0.01 to 2 wt%, relative to the weight of the disinfectant, more preferably 0.1 to 2 wt%, especially 0.2 to 1.5 wt%, such as 0.3 to 1.0 wt%, for example about 0.5 wt%.
  • disinfectants according to the invention contain k) one or more antioxidants.
  • antioxidants are BHA, BHT or vitamin E (or derivatives thereof) , especially preferably vitamin E (or vitamin E-acetate) .
  • the amount of antioxidant is preferably 0.001 to 0.1 wt%, relative to the weight of the disinfectant, preferably 0.002 to 0.05 wt%, such as 0.005 to 0.03 wt%, for example about 0.01 wt%.
  • Skin care agents 1) optionally present in the disinfectant according to the invention are preferably urea, dexpanthenol , hamamelis, bisabolol and/or allantoin.
  • the amount of component 1) (especially dexpanthenol) is preferably 0.01 to 1 wt%, relative to the weight of the disinfectant, preferably 0.02 to 0.5 wt%, such as 0.05 to 0.3 wt%, for example about 0.1 or 0.2 wt%. It is preferred that the disinfectant contains, apart from the mandatory components a) and b) , only 0.05 to 5.0 wt%, preferably 1.0 to 4.0 wt% of further ingredients and water as the remainder.
  • the disinfectant comprises less than 1.0 wt% of water-insoluble polymeric amines (as are described as mandatory component in DE 10 2009 040 089 Al relating to deodorants) .
  • the disinfectant contains less than 0.5 wt% of water-insoluble polymeric amines, especially less than 0.2 wt%, such as for example less than 0.1 wt%, in each case relative to the weight of the disinfectant, wherein especially preferably the disinfectant is free from water-insoluble polymeric amines.
  • disinfectants according to the invention are preferred that comprise less than 1.0 wt% of amino-substituted polystyrenes (as are described as preferred water-insoluble polymeric amines in DE 10 2009 040 089 Al relating to deodorants) .
  • the disinfectant contains less than
  • 0.5 wt% of amino-substituted polystyrenes especially less than 0.2 wt%, for example less than 0.1 wt%, in each case relative to the weight of the disinfectant, wherein especially preferably the disinfectant is free from amino-substituted polystyrenes.
  • the disinfectant comprises less than 10 wt% of C3 alcohol
  • the total amount of 1-propanol and 2-propanol is preferably less than 10 wt%, more preferably less than
  • the disinfectant comprises less than 10 wt% DMSO, preferably less than 8.0 wt%, especially less than 5.0 wt%, for example less than 3.0 wt%, in each case relative to the weight of the disinfectant.
  • the disinfectant according to the invention contains less than 1.0 wt%, especially less than 0.5 wt%, for example less than 0.1 wt% DMSO, in each case relative to the weight of the disinfectant, wherein an especially preferred disinfectant according to the invention is free from DMSO.
  • Disinfectants according to the invention are preferably in the form of solution.
  • the disinfectants according to the invention may be in the form of aqueous-alcoholic gels (hydrogels) .
  • Hydrogels are prized owing to their transparency and their non-greasy character.
  • Lipophilic gels oleogels
  • Gels are mainly intended for external use and should be applied thinly.
  • a hydrogel is a generally translucent mass, which is produced using gelatin, tragacanth, Carbopol or similar swelling substances with addition of water.
  • the disinfectant in the form of gel, it preferably contains
  • fatty acid ester of monovalent Ci to C6 alkyl alcohol preferably isopropyl myristate
  • 0.8 to 1.5 wt% fatty alcohol preferably myristyl alcohol
  • 0.1 to 0.6 wt% thickener preferably polyacrylic acid copolymer
  • complexing agent preferably ⁇ , ⁇ , ⁇ ' , ⁇ '-tetrakis- (2-hydroxypropyl) - ethylenediamine
  • Preferred gels according to the invention further contain d) 0.2 to 3.0 wt% diol (preferably propylene glycol), j) 0.2 to 0.5 wt% sugar alcohol (preferably sorbitol), k) 0.005 to 0.2 wt% of antioxidant (preferably tocopherol and/or tocopherol acetate) ,
  • the invention relates to an alcoholic disinfectant that comprises a) at least 78 wt% ethanol, relative to the weight of the disinfectant, and b) one or more fatty acid esters of monovalent Ci to C6 alkyl alcohol, wherein the disinfectant comprises less than 0.1 wt% glycerin, relative to the weight of the disinfectant, for use for surgical and hygienic disinfection of the hands.
  • the invention relates to the use of fatty acid ester of monovalent Ci to C6 alkyl alcohol for improving the antimicrobial efficacy of an alcoholic disinfectant, wherein the disinfectant comprises at least 78 wt% ethanol, relative to the weight of the disinfectant.
  • this improvement in antimicrobial efficacy is an improvement in the quantitative suspension test according to DGHM (Method 9, Gebel et al .
  • Quantitative suspension test according to DGHM determined at a final concentration in the test of 35% (v/v) of the disinfectant (Gebel et al . (2001) : Standard methods of the DGHM for testing chemical methods of disinfection, mhp Verlag GmbH, as at 1 September 2001) .
  • the individual test samples were prepared at a concentration of 43.75% (v/v) (i.e. 1.25- fold higher in water of standardized hardness (WSH, as described in Gebel et al .
  • the proband test was conducted with blinded samples over a period of 6 weeks. Assessment by the probands (in each case 10) was based on the school grading system from 1 to 6.
  • glycerin has an effect on the efficacy of alcoholic disinfectants in the quantitative suspension test, mainly in the range of amounts of 1 wt% or more that is of interest with respect to use as refatting agent.
  • the effect whereby glycerin actually even lowers the efficacy in the quantitative suspension test in an amount of 1.5 wt%, is especially pronounced in the case of alcoholic disinfectants that contain over 80 wt% ethanol.
  • isopropyl myristate in an amount of 1.5 wt% increases the efficacy of an ethanolic disinfectant in the quantitative suspension test.
  • composition contains 99% ethanol 85.0 g, other constituents: butan-2- one, 1-propanol (Ph. Eur.), tetradecan-l-ol, glycerin 85%, purified water
  • composition according to manufacturer's data: ethanol 45 g, 1-propanol 18 g, other constituents: purified water, diisopropyl adipate, macrogol- 6-glycerin caprylocaprate, dexpanthenol , (+/-) -alpha-bisabolol, odour substances (contain limonene and linalool) , allantoin.
  • composition according to manufacturer's data: 100 g of solution contains 99% ethanol 95.0 g, other constituents butan-2- one, glycerin, tetradecan-l-ol, benzine Table 1: Composition of the agents undergoing haptic assessment
  • Table 2 Presentation of the assessment of various ethanolic formulations for disinfection of the hands

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Emergency Medicine (AREA)
  • Agronomy & Crop Science (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne des désinfectants à base d'alcool, qui comprennent a) au moins 78 % massiques d'éthanol, par rapport au poids du désinfectant, et b) un ou plusieurs esters d'acide gras et d'alcool d'alkyle C1 à C6 monovalent. Les désinfectants contiennent moins de 5,0 % massiques de parfum. En outre, les désinfectants contiennent moins de 0,1 % massique de glycérine et sont donc particulièrement efficaces pour une utilisation pour la désinfection chirurgicale et hygiénique des mains.
EP15781614.1A 2014-10-16 2015-10-08 Utilisation d'ester d'acide gras pour améliorer l'efficacité antimicrobienne d'un désinfectant à base d'alcool Active EP3206487B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL15781614T PL3206487T3 (pl) 2014-10-16 2015-10-08 Zastosowanie estru kwasu tłuszczowego do poprawy skuteczności przeciwdrobnoustrojowej alkoholowego środka dezynfekcyjnego

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014115080.5A DE102014115080A1 (de) 2014-10-16 2014-10-16 Verwendung von Fettsäureester zur Verbesserung der antimikrobiellen Wirksamkeit eines alkoholischen Desinfektionsmittels
PCT/EP2015/073279 WO2016058902A1 (fr) 2014-10-16 2015-10-08 Utilisation d'ester d'acide gras pour améliorer l'efficacité antimicrobienne d'un désinfectant à base d'alcool

Publications (2)

Publication Number Publication Date
EP3206487A1 true EP3206487A1 (fr) 2017-08-23
EP3206487B1 EP3206487B1 (fr) 2021-12-29

Family

ID=54330743

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15781614.1A Active EP3206487B1 (fr) 2014-10-16 2015-10-08 Utilisation d'ester d'acide gras pour améliorer l'efficacité antimicrobienne d'un désinfectant à base d'alcool

Country Status (9)

Country Link
EP (1) EP3206487B1 (fr)
JP (1) JP2017530981A (fr)
CN (1) CN106794166B (fr)
AU (1) AU2015332918A1 (fr)
DE (1) DE102014115080A1 (fr)
MY (1) MY186572A (fr)
PL (1) PL3206487T3 (fr)
SG (1) SG11201703009YA (fr)
WO (1) WO2016058902A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016113210A1 (de) 2016-07-18 2018-01-18 Schülke & Mayr GmbH Alkoholisches desinfektionsmittel mit guter hautpflegewirkung und hoher wirksamkeit
JP2023545647A (ja) * 2020-09-25 2023-10-31 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ 保湿抗菌組成物
CN116157014A (zh) * 2020-10-02 2023-05-23 株式会社资生堂 消毒剂组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH532397A (de) 1972-08-22 1973-01-15 Telephon Hygiene Service Desin Verfahren zur Oberflächen-Assanierung von Gebrauchsgegenständen sowie dafür bestimmtes Mittel
GB1533952A (en) 1976-02-25 1978-11-29 Sterling Drug Inc Anti-microbial bis-pyridinium compounds
US4902676A (en) * 1986-09-29 1990-02-20 Nelson Research & Development Co. Compositions comprising N,N-dialkylalkanamides
JPH02140167A (ja) * 1988-11-22 1990-05-29 Saraya Kk 手指消毒用組成物
DE19612057A1 (de) 1996-03-27 1997-10-02 Antiseptica Chem Pharm Prod Gm Händedesinfektionsmittel
DE19647692C2 (de) 1996-11-05 2002-06-20 Schuelke & Mayr Gmbh Waschendes Desinfektionsmittel zur hygienischen und chirurgischen Händedesinfektion
US6183766B1 (en) 1999-02-12 2001-02-06 The Procter & Gamble Company Skin sanitizing compositions
CA2362613C (fr) 1999-12-13 2010-09-28 Ethicon, Inc. Systemes antimicrobiens stabilises et procedes de production
TW409797U (en) * 1999-12-20 2000-10-21 Li Mau Duen Micro rolling ball sliding rail
WO2001052805A1 (fr) * 2000-01-18 2001-07-26 Unilever Plc Compositions antimicrobiennes comprenant un sel d'un chelateur de metal de transition
US6617294B2 (en) * 2000-10-20 2003-09-09 Vinod K. Narula Waterless sanitizing hand cleanser
JP2004107667A (ja) * 2002-09-18 2004-04-08 Vinod K Narula 手消毒洗浄剤
US6723689B1 (en) * 2003-01-08 2004-04-20 Becton Dickinson And Company Emollient alcohol skin disinfecting formulation
DE102004062775A1 (de) * 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
DE102005002645A1 (de) * 2005-01-19 2006-07-20 Schülke & Mayr GmbH Alkoholische Zusammensetzungen für die Desinfektion
EP1685854B2 (fr) 2005-01-28 2020-06-10 B. Braun Medical AG Composition virucidal en désinfection
ES2785999T3 (es) 2005-05-16 2020-10-08 Novapharm Res Australia Pty Limited Composición para su uso en la preparación de un paciente para cirugía
CA2560138A1 (fr) * 2006-09-19 2008-03-19 Professional Artists International Inc. Procedes pour la desinfection des cosmetiques
WO2009088894A2 (fr) 2007-12-31 2009-07-16 3M Innovative Properties Company Compositions antimicrobiennes
US20120208894A1 (en) * 2008-03-17 2012-08-16 Bode Chemie Gmbh & Co. Kg Multi-purpose hand disinfectant
ES2539952T3 (es) * 2008-06-30 2015-07-07 Schwartz, Arthur Formulaciones esteroideas tópicas
AU2010202421B2 (en) 2009-06-15 2014-05-08 Gojo Industries, Inc. Method and compositions for use with gel dispensers
DE102009040089A1 (de) 2009-09-04 2011-07-21 Beiersdorf AG, 20253 Zubereitungen mit wasserunlöslichen polymeren Aminen zur Verminderung von Körpergeruch
WO2011072728A1 (fr) 2009-12-16 2011-06-23 Ecolab Inc. Composition sous forme de gel utilisée pour la désinfection virucide de la peau d'un mammifère
DE102010054155A1 (de) * 2010-12-10 2012-06-14 Schülke & Mayr GmbH Verwendung von aliphatischen Alkoholen bei der Herstellung eines Desinfektionsmittels zur Verhinderung der Verunreinigung des Desinfektionsmittels mit bakteriellen Sporen
DE102010055528A1 (de) * 2010-12-22 2012-06-28 Bode Chemie Gmbh Antimikrobielle Zusammensetzung mit hautpflegenden Eigenschaften
US9161531B2 (en) 2011-02-23 2015-10-20 Donald R. Korb High alcohol content sanitizer
US9089129B2 (en) 2011-10-07 2015-07-28 American Sterilizer Company Non-aerosol foaming alcohol hand sanitizer
WO2014032696A1 (fr) 2012-08-28 2014-03-06 Ecolab Inc. Composition virucide
US10070644B2 (en) * 2012-12-24 2018-09-11 Novapharm Research (Australlia) Pty Ltd Antimicrobial composition

Also Published As

Publication number Publication date
MY186572A (en) 2021-07-27
CN106794166B (zh) 2020-07-03
CN106794166A (zh) 2017-05-31
JP2017530981A (ja) 2017-10-19
WO2016058902A1 (fr) 2016-04-21
SG11201703009YA (en) 2017-05-30
PL3206487T3 (pl) 2022-05-09
EP3206487B1 (fr) 2021-12-29
DE102014115080A1 (de) 2016-04-21
AU2015332918A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
US8465766B2 (en) Wound and mucous membrane disinfectant
US20130053422A1 (en) Antimicrobial Compositions
EP2443223A2 (fr) Compositions antimicrobiennes
JP2007532542A (ja) 抗菌性組成物
JPH06509564A (ja) 抗菌性混合物
JP2011006434A (ja) マイコバクテリアを制御するための、芳香族アルコールとグリセロールエーテルの混合液に基づく相乗的製剤
US20110237626A1 (en) Compositions for hygienic hand disinfection and disinfectant handwashing
JP2017513951A (ja) フッ化カルシウムを基礎とする改良された殺生物剤組成物及びその使用
EP2664318B1 (fr) Compositions ayant une activité antimicrobiènne comprenant un composé de zinc, de l'éther monoalkylé de glycerine et un antioxidant
EP3206487B1 (fr) Utilisation d'ester d'acide gras pour améliorer l'efficacité antimicrobienne d'un désinfectant à base d'alcool
KR102272901B1 (ko) 메조-2,3-부탄디올을 방부제로서 함유하는 피부 외용제 조성물
US11134680B2 (en) Disinfectant having organic acids
US20120053215A1 (en) Isothiazolone-containing preservative with improved effectiveness
EP3195851A1 (fr) Composition contenant du mésobutane-2,3-diol
KR20170130714A (ko) 차아염소산을 이용한 세정제 조성물 및 이를 포함하는 물티슈
KR101788179B1 (ko) 방부력이 우수한 저자극성 피부 외용제 조성물
US20170231220A1 (en) Antimicrobial composition
JP4999321B2 (ja) 防腐殺菌剤を配合した医薬品、及び防腐殺菌方法
US9907737B2 (en) Composition comprising ferulic acid ethyl ester and aryl alkanol
RU2517031C1 (ru) Биоцидный состав для пропитки салфеток
KR102189174B1 (ko) 산업용 항균제 조성물
WO2026041926A1 (fr) Combinaison synergique d'un peptide antimicrobien et d'agents actifs pour des applications d'hygiène
WO2026042045A1 (fr) Compositions contenant de l'indolicidine pour des applications de soins personnels/d'hygiène

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190115

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SCHUELKE & MAYR GMBH

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 31/02 20060101AFI20210506BHEP

Ipc: A01N 37/02 20060101ALI20210506BHEP

Ipc: A01N 25/30 20060101ALI20210506BHEP

Ipc: A01P 1/00 20060101ALI20210506BHEP

Ipc: A61P 31/02 20060101ALI20210506BHEP

Ipc: A61P 31/12 20060101ALI20210506BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210706

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015076091

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1458004

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220329

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220330

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220429

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602015076091

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20220429

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

26 Opposition filed

Opponent name: BODE CHEMIE GMBH & CO.

Effective date: 20220929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1458004

Country of ref document: AT

Kind code of ref document: T

Effective date: 20211229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221031

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221008

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221008

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151008

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20250926

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251021

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211229

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251021

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20251022

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251101

Year of fee payment: 11

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271